{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:30:28Z","timestamp":1786433428987,"version":"build-2736575974"},"reference-count":133,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"DOI":"10.13039\/spjdxdrm188y","name":"National Medical Research Council Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/spjdxdrm188y","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"abstract":"<jats:p>The cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome is a major and growing global health burden, with disproportionate impact among socioeconomically disadvantaged populations. It reflects the interconnectedness of cardiovascular disease, CKD, and metabolic dysfunction, driven by excess adiposity (particularly visceral obesity and ectopic fat deposition), insulin resistance, inflammation, vascular dysfunction, and other metabolic perturbations. The American Heart Association introduced the CKM syndrome framework, defining a five-stage (0\u20134) continuum that captures progressive risk of cardiovascular morbidity and mortality. The American Heart Association also proposed a CKM health framework that emphasizes multidisciplinary care of patients with CKM syndrome for early detection, monitoring, and prevention at the health systems and population health levels. This approach is aligned with the integrated cardio\u2013kidney\u2013metabolic care principles advocated by key professional societies such as the American Society of Nephrology, Kidney Disease Improving Global Outcomes, and the American Diabetes Association. This review synthesized current evidence on the development and progression of CKM syndrome, highlighting the important roles of biologic mechanisms, shared risk factors, and social determinants of health in driving its complex, multidirectional pathophysiology. We summarized key components of the CKM health framework and discussed how combining lifestyle interventions with CKM-targeted, multidisease-modifying pharmacotherapies often necessitates a multidisciplinary approach to optimize CKM care. Finally, we outlined practical considerations and emerging strategies for coadapting and integrating CKM care into routine clinical practice, drawing on implementation frameworks to enhance feasibility, adoption, and sustainability. These efforts may help inform ongoing multicenter initiatives to develop CKM clinical practice and public health guidelines and ultimately address underlying risk factors and social determinants of health to reduce cardiovascular, kidney, and metabolic morbidity and mortality.<\/jats:p>","DOI":"10.2215\/cjn.0000001173","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:01:01Z","timestamp":1782921661000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["From Risk Determinants to Clinical Action"],"prefix":"10.2215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7454-8376","authenticated-orcid":false,"given":"Tazeen H.","family":"Jafar","sequence":"first","affiliation":[{"name":"Program in Health Services Research and Population Health, Duke-NUS Medical School, Singapore"},{"name":"Duke Global Health Institute, Durham, North Carolina"},{"name":"Department of Renal Medicine, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7959-0104","authenticated-orcid":false,"given":"Anqi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Program in Health Services Research and Population Health, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-0906","authenticated-orcid":false,"given":"Oluwabunmi","family":"Ogungbe","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Johns Hopkins School of Nursing, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"20","key":"B1-20260811","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation."},{"issue":"20","key":"B2-20260811","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation."},{"issue":"9","key":"B3-20260811","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","article-title":"Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement","volume":"7","author":"Neeland","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"B4-20260811","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B5-20260811","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001453","article-title":"2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","author":"Ndumele","year":"2026","journal-title":"Circulation."},{"issue":"7","key":"B6-20260811","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1681\/ASN.0000000637","article-title":"Cumulative incidence of mortality associated with cardiovascular-kidney-metabolic (CKM) syndrome","volume":"36","author":"Claudel","year":"2025","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B7-20260811","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/biom15020213","article-title":"From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework","volume":"15","author":"Theodorakis","year":"2025","journal-title":"Biomolecules."},{"issue":"10322","key":"B8-20260811","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet."},{"issue":"20","key":"B9-20260811","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.jacc.2025.08.086","article-title":"Chronic kidney disease in patients with heart failure with a preserved ejection fraction: the underlying role of visceral adiposity","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"B10-20260811","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1463-1326.2006.00594.x","article-title":"Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease","volume":"9","author":"Rana","year":"2007","journal-title":"Diabetes Obes Metab."},{"issue":"10159","key":"B11-20260811","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet."},{"issue":"21","key":"B12-20260811","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA."},{"issue":"8","key":"B13-20260811","doi-asserted-by":"crossref","first-page":"e70137","DOI":"10.1111\/1753-0407.70137","article-title":"Association between serum advanced glycation end products and cardiovascular-kidney-metabolic (CKM) syndrome: a 3-year longitudinal cohort study (2019-2022)","volume":"17","author":"Zhao","year":"2025","journal-title":"J Diabetes."},{"key":"B14-20260811","doi-asserted-by":"crossref","first-page":"101369","DOI":"10.1016\/j.ajpc.2025.101369","article-title":"Cardiovascular-kidney-metabolic syndrome stages and increased risk of all-cause and cause-specific mortality in UK Biobank","volume":"25","author":"Xu","year":"2026","journal-title":"Am J Prev Cardiol."},{"issue":"1","key":"B15-20260811","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12933-024-02251-w","article-title":"Is systemic inflammation a missing link between cardiometabolic index with mortality? Evidence from a large population-based study","volume":"23","author":"Xu","year":"2024","journal-title":"Cardiovasc Diabetol."},{"issue":"12","key":"B16-20260811","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat Med."},{"issue":"3","key":"B17-20260811","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am J Physiol Cell Physiol."},{"issue":"6","key":"B18-20260811","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41569-023-00964-1","article-title":"Immune and inflammatory mechanisms in hypertension","volume":"21","author":"Guzik","year":"2024","journal-title":"Nat Rev Cardiol."},{"issue":"4","key":"B19-20260811","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/STROKEAHA.124.047070","article-title":"The kidney-immune-brain axis: the role of inflammation in the pathogenesis and treatment of stroke in chronic kidney disease","volume":"56","author":"Kelly","year":"2025","journal-title":"Stroke."},{"issue":"10","key":"B20-20260811","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tem.2015.08.001","article-title":"The IL-1 pathway in type 2 diabetes and cardiovascular complications","volume":"26","author":"Herder","year":"2015","journal-title":"Trends Endocrinol Metab."},{"issue":"9709","key":"B21-20260811","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet."},{"issue":"1","key":"B22-20260811","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12916-022-02446-6","article-title":"Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups","volume":"20","author":"Georgakis","year":"2022","journal-title":"BMC Med."},{"key":"B23-20260811","doi-asserted-by":"crossref","first-page":"103062","DOI":"10.1016\/j.ebiom.2020.103062","article-title":"Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes","volume":"61","author":"Bowker","year":"2020","journal-title":"EBioMedicine."},{"issue":"9","key":"B24-20260811","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2215\/CJN.13121215","article-title":"Inflammation and progression of CKD: the CRIC study","volume":"11","author":"Amdur","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B25-20260811","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/ATVBAHA.120.315793","article-title":"IL-6 as a mediator of the association between traditional risk factors and future myocardial infarction: a nested case-control study","volume":"41","author":"Zegeye","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"1","key":"B26-20260811","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1186\/s12872-025-05135-3","article-title":"Fat distribution, inflammatory mechanisms, and cardiovascular disease risk: mediation analysis based on the Framingham risk score","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Cardiovasc Disord."},{"issue":"19","key":"B27-20260811","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med."},{"issue":"11","key":"B28-20260811","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2025.08.047","article-title":"Inflammation and cardiovascular disease: 2025 ACC scientific statement","volume":"87","author":"Mensah","year":"2026","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"B29-20260811","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"issue":"7","key":"B30-20260811","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.ekir.2021.04.023","article-title":"Chronic inflammation in chronic kidney disease progression: role of Nrf2","volume":"6","author":"Stenvinkel","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"18","key":"B31-20260811","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.3390\/cells11182825","article-title":"HIV-related myocardial fibrosis: Inflammatory hypothesis and crucial role of immune cells dysregulation","volume":"11","author":"Teer","year":"2022","journal-title":"Cells."},{"issue":"19","key":"B32-20260811","doi-asserted-by":"crossref","first-page":"eabm5371","DOI":"10.1126\/sciadv.abm5371","article-title":"Influenza virus replication in cardiomyocytes drives heart dysfunction and fibrosis","volume":"8","author":"Kenney","year":"2022","journal-title":"Sci Adv."},{"issue":"3","key":"B34-20260811","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.123.21354","article-title":"Social determinants of health and disparities in hypertension and cardiovascular diseases","volume":"81","author":"Chaturvedi","year":"2024","journal-title":"Hypertension."},{"issue":"1","key":"B35-20260811","doi-asserted-by":"crossref","first-page":"e000124","DOI":"10.1161\/HCQ.0000000000000124","article-title":"Neighborhoods and cardiovascular health: a scientific statement from the American Heart Association","volume":"17","author":"Kershaw","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"3","key":"B36-20260811","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/geronb\/gby108","article-title":"Socioeconomic status and biological risks for health and illness across the life course","volume":"75","author":"Yang","year":"2020","journal-title":"J Gerontol B Psychol Sci Soc Sci."},{"issue":"7","key":"B37-20260811","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/s41591-023-02426-0","article-title":"Adverse childhood experiences and lifelong health","volume":"29","author":"Bhutta","year":"2023","journal-title":"Nat Med."},{"issue":"4","key":"B38-20260811","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s41390-022-01933-z","article-title":"Perinatal and early childhood biomarkers of psychosocial stress and adverse experiences","volume":"92","author":"Barrero-Castillero","year":"2022","journal-title":"Pediatr Res."},{"issue":"1","key":"B39-20260811","doi-asserted-by":"crossref","first-page":"e044079","DOI":"10.1161\/JAHA.125.044079","article-title":"JAHA at scientific sessions 2024: climate change-related cardiovascular health effects in the global south","volume":"15","author":"Navas-Acien","year":"2026","journal-title":"J Am Heart Assoc."},{"issue":"2","key":"B40-20260811","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/advances\/nmaa107","article-title":"Early-life nutrition interventions and associated long-term cardiometabolic outcomes: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"He","year":"2021","journal-title":"Adv Nutr."},{"issue":"1","key":"B41-20260811","doi-asserted-by":"crossref","first-page":"e2351752","DOI":"10.1001\/jamanetworkopen.2023.51752","article-title":"Early home visits and health outcomes in low-income mothers and offspring: 18-year follow-up of a randomized clinical trial","volume":"7","author":"Conti","year":"2024","journal-title":"JAMA Netw Open."},{"key":"B42-20260811","doi-asserted-by":"crossref","first-page":"h770","DOI":"10.1136\/bmj.h770","article-title":"School based education programme to reduce salt intake in children and their families (School-EduSalt): cluster randomised controlled trial","volume":"350","author":"He","year":"2015","journal-title":"BMJ."},{"issue":"18","key":"B43-20260811","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1161\/CIR.0000000000000961","article-title":"Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association","volume":"143","author":"Parikh","year":"2021","journal-title":"Circulation."},{"issue":"6","key":"B44-20260811","doi-asserted-by":"crossref","first-page":"e1004629","DOI":"10.1371\/journal.pmed.1004629","article-title":"Cardiovascular-kidney-metabolic syndrome and all-cause and cardiovascular mortality: a retrospective cohort study","volume":"22","author":"Tsai","year":"2025","journal-title":"PLoS Med."},{"key":"B45-20260811","doi-asserted-by":"crossref","first-page":"103596","DOI":"10.1016\/j.eclinm.2025.103596","article-title":"Association between cardiovascular-kidney-metabolic syndrome, lifestyle, and all-cause and cause-specific mortality: a prospective cohort study","volume":"90","author":"Wang","year":"2025","journal-title":"EClinicalMedicine."},{"issue":"4","key":"B46-20260811","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1681\/ASN.2014010108","article-title":"High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"26","author":"Bansal","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B47-20260811","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA."},{"issue":"24","key":"B48-20260811","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation."},{"issue":"10","key":"B49-20260811","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","article-title":"Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review","volume":"151","author":"Claudel","year":"2025","journal-title":"Circulation."},{"issue":"9","key":"B50-20260811","doi-asserted-by":"crossref","first-page":"102581","DOI":"10.1016\/j.jchf.2025.102581","article-title":"Heart failure in advanced chronic kidney disease: overlooked no more","volume":"13","author":"de la Espriella","year":"2025","journal-title":"JACC Heart Fail."},{"issue":"15","key":"B51-20260811","doi-asserted-by":"crossref","first-page":"e015410","DOI":"10.1161\/JAHA.119.015410","article-title":"Combining biomarkers and imaging for short\u2010term assessment of cardiovascular disease risk in apparently healthy adults","volume":"9","author":"Gore","year":"2020","journal-title":"J Am Heart Assoc."},{"issue":"10302","key":"B52-20260811","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet."},{"issue":"4","key":"B53-20260811","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2215\/CJN.06610810","article-title":"Multidisciplinary team care may slow the rate of decline in renal function","volume":"6","author":"Bayliss","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"B54-20260811","doi-asserted-by":"crossref","first-page":"sfae331","DOI":"10.1093\/ckj\/sfae331","article-title":"Integrated, person-centred care for patients with complex cardiovascular disease, diabetes mellitus and chronic kidney disease: a randomized trial","volume":"17","author":"Ev\u00e9n","year":"2024","journal-title":"Clin Kidney J."},{"issue":"2","key":"B55-20260811","doi-asserted-by":"crossref","first-page":"108389","DOI":"10.1016\/j.jdiacomp.2022.108389","article-title":"Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases","volume":"37","author":"Handelsman","year":"2023","journal-title":"J Diabetes Complications."},{"issue":"6 Pt 2","key":"B56-20260811","doi-asserted-by":"crossref","first-page":"101788","DOI":"10.1016\/j.jacadv.2025.101788","article-title":"Lifestyle interventions in cardiovascular-kidney-metabolic syndrome JACC: advances expert panel","volume":"4","author":"Shahid","year":"2025","journal-title":"JACC Adv."},{"issue":"5","key":"B57-20260811","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life's Essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation."},{"issue":"4","key":"B58-20260811","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1161\/CIR.0000000000001258","article-title":"Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: a presidential advisory from the American Heart Association","volume":"150","author":"Kazi","year":"2024","journal-title":"Circulation."},{"issue":"10","key":"B59-20260811","doi-asserted-by":"crossref","first-page":"104130","DOI":"10.1016\/j.numecd.2025.104130","article-title":"The effectiveness of lifestyle interventions in reducing cardiovascular risk and risk factors in people with prediabetes: a systematic review and meta-analysis","volume":"35","author":"Demissie","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"25","key":"B60-20260811","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"B61-20260811","first-page":"e202503","article-title":"The role of microbiome dysbiosis in cardiovascular disease: mechanisms and therapeutic implications","volume":"2025","author":"Abdulaal","year":"2025","journal-title":"Glob Cardiol Sci Pract."},{"issue":"6 Pt 2","key":"B62-20260811","doi-asserted-by":"crossref","first-page":"101795","DOI":"10.1016\/j.jacadv.2025.101795","article-title":"DASH diet adherence and cardiovascular-kidney metabolic syndrome stages: National Health and Nutrition Examination Survey 2011-2020","volume":"4","author":"Akubo","year":"2025","journal-title":"JACC Adv."},{"issue":"22","key":"B63-20260811","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1161\/CIR.0000000000001146","article-title":"Popular dietary patterns: alignment with American Heart Association 2021 dietary guidance: a scientific statement from the American Heart Association","volume":"147","author":"Gardner","year":"2023","journal-title":"Circulation."},{"key":"B64-20260811","doi-asserted-by":"crossref","first-page":"112181","DOI":"10.1016\/j.mad.2026.112181","article-title":"Curvilinear dose-response association of physical activity with clinically diagnosed stress: prospective cohort with 74,000 individuals","volume":"231","author":"Andersen","year":"2026","journal-title":"Mech Ageing Dev."},{"issue":"3","key":"B65-20260811","first-page":"CD008286","article-title":"Combined pharmacotherapy and behavioural interventions for smoking cessation","volume":"3","author":"Stead","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"issue":"11","key":"B66-20260811","doi-asserted-by":"crossref","first-page":"e1004561","DOI":"10.1371\/journal.pmed.1004561","article-title":"Association between cigarette smoking status, intensity, and cessation duration with long-term incidence of nine cardiovascular and mortality outcomes: the cross-cohort collaboration (CCC)","volume":"22","author":"Tasdighi","year":"2025","journal-title":"PLoS Med."},{"issue":"4","key":"B67-20260811","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jamainternmed.2022.7170","article-title":"The effects of opt-out vs opt-in tobacco treatment on engagement, cessation, and costs: a randomized clinical trial","volume":"183","author":"Richter","year":"2023","journal-title":"JAMA Intern Med."},{"issue":"7","key":"B68-20260811","doi-asserted-by":"crossref","first-page":"e038674","DOI":"10.1161\/JAHA.124.038674","article-title":"Overall sleep quality is associated with advanced stages in patients with cardiovascular-kidney-metabolic syndrome","volume":"14","author":"Tu","year":"2025","journal-title":"J Am Heart Assoc."},{"issue":"3","key":"B69-20260811","doi-asserted-by":"crossref","first-page":"e243779","DOI":"10.1001\/jamanetworkopen.2024.3779","article-title":"Shared decision-making in cardiovascular risk factor management: a systematic review and meta-analysis","volume":"7","author":"Elias","year":"2024","journal-title":"JAMA Netw Open."},{"key":"B70-20260811","doi-asserted-by":"crossref","first-page":"101388","DOI":"10.1016\/j.eclinm.2022.101388","article-title":"Determining the frequency and level of task-sharing for hypertension management in LMICs: a systematic review and meta-analysis","volume":"47","author":"Ogungbe","year":"2022","journal-title":"EClinicalMedicine."},{"issue":"23","key":"B71-20260811","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"B72-20260811","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/ndt\/gfz122","article-title":"Proprotein convertase subtilisin\/kexin type 9 in kidney disease","volume":"34","author":"Schmit","year":"2019","journal-title":"Nephrol Dial Transplant."},{"issue":"9784","key":"B73-20260811","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"issue":"15","key":"B74-20260811","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"issue":"10254","key":"B75-20260811","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet."},{"issue":"15","key":"B76-20260811","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"25","key":"B77-20260811","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol."},{"issue":"4S","key":"B78-20260811","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"18","key":"B79-20260811","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation."},{"issue":"1","key":"B80-20260811","doi-asserted-by":"crossref","first-page":"9641","DOI":"10.1038\/s41467-025-64640-3","article-title":"Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun."},{"issue":"7","key":"B81-20260811","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamacardio.2025.1101","article-title":"Finerenone in heart failure with improved ejection fraction: the FINEARTS-HF randomized clinical trial","volume":"10","author":"Pabon","year":"2025","journal-title":"JAMA Cardiol."},{"issue":"1","key":"B82-20260811","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation."},{"issue":"12","key":"B83-20260811","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurheartj\/ehae613","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial","volume":"46","author":"Mahaffey","year":"2025","journal-title":"Eur Heart J."},{"issue":"suppl 1","key":"B84-20260811","first-page":"S183","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care."},{"issue":"suppl 1","key":"B85-20260811","first-page":"S216","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care."},{"issue":"6","key":"B86-20260811","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation."},{"issue":"3","key":"B87-20260811","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4093\/dmj.2025.0220","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease: evolving evidence and clinical application","volume":"49","author":"Bae","year":"2025","journal-title":"Diabetes Metab J."},{"issue":"2","key":"B88-20260811","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"issue":"12","key":"B89-20260811","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med."},{"issue":"9","key":"B90-20260811","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"B91-20260811","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12933-025-03007-w","article-title":"Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials","volume":"24","author":"Peng","year":"2025","journal-title":"Cardiovasc Diabetol."},{"issue":"2","key":"B92-20260811","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"4","key":"B93-20260811","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"8","key":"B94-20260811","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10508","key":"B95-20260811","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(25)01384-4","article-title":"Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention","volume":"406","author":"Ostrominski","year":"2025","journal-title":"Lancet."},{"issue":"8","key":"B96-20260811","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"suppl 1","key":"B97-20260811","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","article-title":"Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease","volume":"40","author":"Alicic","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"23","key":"B98-20260811","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"24","key":"B99-20260811","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med."},{"issue":"16","key":"B100-20260811","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med."},{"key":"B101-20260811","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-2369-15-64","article-title":"Primary care physicians' familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study","volume":"15","author":"Abdel-Kader","year":"2014","journal-title":"BMC Nephrol."},{"issue":"7","key":"B102-20260811","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s11606-019-04975-y","article-title":"Primary care physicians' perceived barriers to nephrology referral and co-management of patients with CKD: a qualitative study","volume":"34","author":"Greer","year":"2019","journal-title":"J Gen Intern Med."},{"issue":"3","key":"B103-20260811","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/gfac283","article-title":"Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease","volume":"38","author":"Nee","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"10","key":"B104-20260811","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1111\/dom.15789","article-title":"Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: a comprehensive review and call to action","volume":"26","author":"Czupryniak","year":"2024","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"B105-20260811","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium","volume":"78","author":"Shin","year":"2021","journal-title":"Hypertension."},{"issue":"5","key":"B106-20260811","doi-asserted-by":"crossref","first-page":"e067386","DOI":"10.1136\/bmjopen-2022-067386","article-title":"Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study","volume":"13","author":"Tangri","year":"2023","journal-title":"BMJ Open."},{"issue":"6","key":"B107-20260811","doi-asserted-by":"crossref","first-page":"e2418808","DOI":"10.1001\/jamanetworkopen.2024.18808","article-title":"Concordance with screening and treatment guidelines for chronic kidney disease in type 2 diabetes","volume":"7","author":"Edmonston","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"9","key":"B108-20260811","doi-asserted-by":"crossref","first-page":"e023507","DOI":"10.1136\/bmjopen-2018-023507","article-title":"Work of being an adult patient with chronic kidney disease: a systematic review of qualitative studies","volume":"8","author":"Roberti","year":"2018","journal-title":"BMJ Open."},{"issue":"9","key":"B110-20260811","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2215\/CJN.0000000744","article-title":"The cardiovascular-kidney-metabolic health framework: implications for nephrology","volume":"20","author":"Rangaswami","year":"2025","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B111-20260811","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","article-title":"The updated consolidated framework for implementation research based on user feedback","volume":"17","author":"Damschroder","year":"2022","journal-title":"Implement Sci."},{"key":"B112-20260811","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","article-title":"RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review","volume":"7","author":"Glasgow","year":"2019","journal-title":"Front Public Health."},{"issue":"1","key":"B113-20260811","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s43058-026-00854-w","article-title":"Adaptation of a cardiovascular quality improvement initiative for worksite health centers: application of the ADAPT-ITT framework","volume":"7","author":"Jiang","year":"2026","journal-title":"Implement Sci Commun."},{"issue":"3","key":"B114-20260811","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.124.068962","article-title":"Effects of an intervention to improve evidence-based care for people with diabetes and cardiovascular disease across sex, race, and ethnicity subgroups: insights from the COORDINATE-diabetes trial","volume":"150","author":"Tannu","year":"2024","journal-title":"Circulation."},{"issue":"17","key":"B115-20260811","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2023.19129","article-title":"The inflation reduction act and access to high-cost cardiovascular therapies","volume":"330","author":"Kazi","year":"2023","journal-title":"JAMA."},{"issue":"702","key":"B116-20260811","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.3399\/bjgp20X714199","article-title":"Multicomponent interventions for enhancing primary care: a systematic review","volume":"71","author":"Jimenez","year":"2021","journal-title":"Br J Gen Pract."},{"issue":"5","key":"B117-20260811","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.amepre.2015.04.006","article-title":"Clinical decision support systems and prevention: a community guide cardiovascular disease systematic review","volume":"49","author":"Njie","year":"2015","journal-title":"Am J Prev Med."},{"issue":"1","key":"B118-20260811","doi-asserted-by":"crossref","first-page":"e2453745","DOI":"10.1001\/jamanetworkopen.2024.53745","article-title":"Clinical decision support and cardiometabolic medication adherence: a randomized clinical trial","volume":"8","author":"O'Connor","year":"2025","journal-title":"JAMA Netw Open."},{"issue":"19","key":"B119-20260811","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1161\/CIR.0000000000001382","article-title":"Opportunistic detection of coronary artery calcium on noncardiac chest computed tomography: an emerging tool for cardiovascular disease prevention: a scientific statement from the American Heart Association","volume":"152","author":"Foraker","year":"2025","journal-title":"Circulation."},{"issue":"23","key":"B120-20260811","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1001\/jama.2025.19563","article-title":"An AI-powered lifestyle intervention vs human coaching in the diabetes prevention program: a randomized clinical trial","volume":"334","author":"Mathioudakis","year":"2025","journal-title":"JAMA."},{"issue":"40","key":"B121-20260811","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1093\/eurheartj\/ehae465","article-title":"Artificial intelligence in cardiovascular medicine: clinical applications","volume":"45","author":"Luscher","year":"2024","journal-title":"Eur Heart J."},{"issue":"1","key":"B122-20260811","doi-asserted-by":"crossref","first-page":"e021298","DOI":"10.1136\/bmjgh-2025-021298","article-title":"Readiness to deliver integrated cardiovascular, kidney and metabolic care in primary healthcare: phase II of HEARTS 2.0 in 26 countries in the Americas","volume":"11","author":"Ordunez","year":"2026","journal-title":"BMJ Glob Health."},{"issue":"8","key":"B123-20260811","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1911965","article-title":"A community-based intervention for managing hypertension in rural south Asia","volume":"382","author":"Jafar","year":"2020","journal-title":"N Engl J Med."},{"issue":"22","key":"B124-20260811","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2025.09.1531","article-title":"Improving global cardiovascular health by integrating primary and community-based care","volume":"86","author":"Yan","year":"2025","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"B125-20260811","doi-asserted-by":"crossref","first-page":"e1002311","DOI":"10.1371\/journal.pmed.1002311","article-title":"Reducing US cardiovascular disease burden and disparities through national and targeted dietary policies: a modelling study","volume":"14","author":"Pearson-Stuttard","year":"2017","journal-title":"PLoS Med."},{"issue":"17","key":"B126-20260811","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1161\/CIRCULATIONAHA.121.053678","article-title":"Health impact and cost-effectiveness of achieving the national salt and sugar reduction initiative voluntary sugar reduction targets in the United States: a microsimulation study","volume":"144","author":"Shangguan","year":"2021","journal-title":"Circulation."},{"issue":"12","key":"B127-20260811","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"issue":"9299","key":"B128-20260811","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/S0140-6736(01)07186-0","article-title":"Blood-pressure reduction and cardiovascular risk in HOPE study","volume":"358","author":"Sleight","year":"2001","journal-title":"Lancet."},{"issue":"22","key":"B129-20260811","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"10193","key":"B130-20260811","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"issue":"19","key":"B131-20260811","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"10","key":"B132-20260811","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med."},{"issue":"11","key":"B133-20260811","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"issue":"10","key":"B134-20260811","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med."},{"issue":"16","key":"B135-20260811","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:00:24Z","timestamp":1786431624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001173"}},"subtitle":["Understanding and Implementing the Cardiovascular\u2011Kidney\u2011Metabolic Syndrome Framework"],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":133,"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001173","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}